Denali Therapeutics Inc. (DNLI)
undefined
undefined%
At close: undefined
22.97
0.04%
After-hours Dec 13, 2024, 04:15 PM EST

Denali Therapeutics Statistics

Share Statistics

Denali Therapeutics has 143.92M shares outstanding. The number of shares has increased by 4.18% in one year.

Shares Outstanding 143.92M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.39%
Owned by Institutions (%) n/a
Shares Floating 124.63M
Failed to Deliver (FTD) Shares 6.69K
FTD / Avg. Volume 0.82%

Short Selling Information

The latest short interest is 7.43M, so 5.16% of the outstanding shares have been sold short.

Short Interest 7.43M
Short % of Shares Out 5.16%
Short % of Float 5.96%
Short Ratio (days to cover) 11.35

Valuation Ratios

The PE ratio is -20.3 and the forward PE ratio is -10.87.

PE Ratio -20.3
Forward PE -10.87
PS Ratio 8.92
Forward PS 48
PB Ratio 2.86
P/FCF Ratio -7.95
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Denali Therapeutics Inc. has an Enterprise Value (EV) of 2.87B.

EV / Earnings -19.78
EV / Sales 8.69
EV / EBITDA -15.96
EV / EBIT -14.61
EV / FCF -7.75

Financial Position

The company has a current ratio of 13.65, with a Debt / Equity ratio of 0.

Current Ratio 13.65
Quick Ratio 13.65
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage 0

Financial Efficiency

Return on equity (ROE) is -0.14% and return on capital (ROIC) is -18.16%.

Return on Equity (ROE) -0.14%
Return on Assets (ROA) -0.13%
Return on Capital (ROIC) -18.16%
Revenue Per Employee 847.52K
Profits Per Employee -372.37K
Employee Count 390
Asset Turnover 0.29
Inventory Turnover 0

Taxes

Income Tax 30.00K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by 0.09% in the last 52 weeks. The beta is 1.39, so Denali Therapeutics 's price volatility has been higher than the market average.

Beta 1.39
52-Week Price Change 0.09%
50-Day Moving Average 26.45
200-Day Moving Average 23.03
Relative Strength Index (RSI) 38.84
Average Volume (20 Days) 817.87K

Income Statement

In the last 12 months, Denali Therapeutics had revenue of $330.53M and earned -$145.22M in profits. Earnings per share was $-1.06.

Revenue 330.53M
Gross Profit 313.81M
Operating Income -196.70M
Net Income -145.22M
EBITDA -179.97M
EBIT -196.70M
Earnings Per Share (EPS) -1.06
Full Income Statement

Balance Sheet

The company has $127.11M in cash and $52.24M in debt, giving a net cash position of $74.86M.

Cash & Cash Equivalents 127.11M
Total Debt 52.24M
Net Cash 74.86M
Retained Earnings -1.12B
Total Assets 1.45B
Working Capital 781.75M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$357.99M and capital expenditures -$12.94M, giving a free cash flow of -$370.93M.

Operating Cash Flow -357.99M
Capital Expenditures -12.94M
Free Cash Flow -370.93M
FCF Per Share -2.7
Full Cash Flow Statement

Margins

Gross margin is 94.94%, with operating and profit margins of -59.51% and -43.94%.

Gross Margin 94.94%
Operating Margin -59.51%
Pretax Margin -43.93%
Profit Margin -43.94%
EBITDA Margin -54.45%
EBIT Margin -59.51%
FCF Margin -112.22%

Dividends & Yields

DNLI does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -4.62%
FCF Yield -11.23%
Dividend Details

Analyst Forecast

The average price target for DNLI is $32, which is 39.4% higher than the current price. The consensus rating is "Buy".

Price Target $32
Price Target Difference 39.4%
Analyst Consensus Buy
Analyst Count 11
Stock Forecasts

Scores

Altman Z-Score 12.87
Piotroski F-Score 2